Champions Oncology Revenue, Profits - CSBR Annual Income Statement

Add to My Stocks
$13.98 $1.68 (13.66%) CSBR stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Champions Oncology stock price alone is not sufficient. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $15.41M for 2017 impacts the CSBR stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Champions Oncology profit and loss statement for 2017 total to $12.51M. This line item shows that the operating expenses has decreased compared with last year. Also check: Champions Oncology assets and Champions Oncology free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is May - Apr201720162015201420132012201120102009
Champions Oncology Revenues or Net Sales
15.41M11.18M8.86M11.55M8.32M7.14M6.88M4.89M3.71M
Cost Of Goods Sold (COGS)9.7M8.68M7.63M6.26M5.32M4.89M3.14M1.97M1.98M
Champions Oncology Gross Profit
5.7M2.49M1.23M5.28M2.99M2.25M3.74M2.91M1.73M
Research & Development Expense4.29M4.19M4.84M2.26M1.92M2.93M2.95M2.69M1.72M
Selling General & Admin Expense8.22M8.61M9.62M9.28M7.29M8.37M6.02M3.14M2.33M
Income Before Depreciation Depletion Amortization-6.8M-10.31M-13.23M-6.25M-6.22M-9.06M-5.23M-2.92M-2.33M
Depreciation Depletion Amortization---------
Non Operating Income-0.05M-0.03M--1.12M-0.09M-1.44M--
Interest Expense---------
Champions Oncology Pretax Income
-6.86M-10.35M-13.01M-7.38M-6.32M-8.66M-3.79M-2.92M-2.24M
Provision for Income Taxes---------
MinorityInterest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-6.88M-10.44M-13.14M-7.4M-6.33M-8.66M-3.8M-2.92M-2.24M
Extraordinary Items & Discontinued Operations---------
Champions Oncology Profit/ Loss (Net Income)
-6.88M-10.44M-13.14M-7.4M-6.33M-8.66M-3.8M-2.92M-2.24M
Average Shares used to compute Diluted EPS10.76M8.71M6.08M5.61M4.34M3.9M3.17M2.81M-
Average Shares used to compute Basic EPS10.76M8.71M6.08M5.61M4.34M3.9M3.17M2.81M-
Income Before Nonrecurring Items-6.88M-10.45M-13.14M-7.41M-6.33M-8.66M-3.8M-2.92M-
Income from Nonrecurring Items---------
Champions Oncology Earnings Per Share Basic Net
-0.64-1.20-2.16-1.32-1.44-2.28-1.20-1.08-0.96
Champions Oncology Earnings Per Share Diluted Net
-0.64-1.20-2.16-1.32-1.44-2.28-1.20-1.08-0.96
EPS Diluted Before Nonrecurring Items-0.64-1.20-2.16-1.32-1.44-2.28-1.20-1.08-0.96
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Champions Oncology stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the Champions Oncology revenue chart, as is the case with Champions Oncology indicates a growing business. One needs to compare the YoY topline or sales growth of CSBR stock with its peers like PCSA stock and VNLPY stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-6.88M for CSBR stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The CSBR financials along with Champions Oncology historical stock prices provide a lot of details about the firm.

Champions Oncology Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
7.86
Operating Margin
7.7
Net Profit Margin
7.7
Dividend Yield
0%